Memorial Hospital Research Laboratories

The Cristina Antonescu Lab


Dr Cristina R. Antonescu (MD)
Cristina R. Antonescu, MD
Director, Soft Tissue and Bone Pathology

An on-going focus of our work is the genomic investigation of pediatric and young adult unclassified mesenchymal tumors, with a special emphasis on detecting novel gene fusions drivers. By applying highly efficient RNAseq and FusionSeq pipelines for novel translocation discovery in tumors that lack known genetic alterations, we are able to identify potential new gene rearrangements. After validation with custom designed BAC probes, the fusion candidates are screened in additional sarcoma samples with similar characteristics to establish their recurrent potential. If these gene fusions correlate with unique morphologic, immunophenotypic and clinical findings, then it is likely to define new, stand-alone pathologic entities. These validated fusions are then used as biomarkers of disease and incorporated as diagnostic molecular tests.

A subset of gene fusions characterized by our lab is then selected for in vitro translocation engineering. In addition to establish preclinical models for sarcomas, our work also investigates the pathogenetic mechanisms of gene fusion promiscuity in human neoplasia, specifically how identical translocations expressed in various cell lineages and/or at differentiation stages, with or without cooperating secondary genetic events, result in a wide spectrum of neoplastic disorders.

As the spectrum of tumors driven by these fusions include multiple lines of differentiation, we selected human embryonic stem (hES) cells as an optimal system for in vitro translocation engineering. Our approach uses an innovative and step-wise approach combining CRISPR-Cas9 technology with homology-directed repair (HDR) in the hES cellular context, followed by differentiation to an appropriate cell type [hES-derived mesenchymal precursor (hES-MP) or neural crest (hES-NC)], and conditional expression of the fusion gene from its endogenous locus.


View Lab Overview

Antonescu Team - From top to bottom, left to right: Patricia Sung, William Mallen, Cristina Antonescu, Brigita Meskauskaite, Fabio Vanoli and Laurie Herviou


Rosenbaum E, Jadeja B, Xu B, Zhang L, Agaram NP, Travis W, Singer S, Tap WD, Antonescu CR. (2020). Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Mod Pathol.; 33:591-602

Antonescu CR, Kao YC, Xu B, Fujisawa Y, Chung C, Fletcher CDM, Graf N, Suurmeijer AJ, Zin A, Wexler LH, Ferrari A, Bisogno G, Alaggio R. (2020) Undifferentiated round cell sarcoma with BCOR internal tandem duplications (ITD) or YWHAE fusions: a clinicopathologic and molecular study. Mod Pathol.; 33:1669-1677.

Kao YC, Suurmeijer AJH, Argani P, Dickson BC, Zhang L, Sung YS, Agaram NP, Fletcher CDM, Antonescu CR. (2020). Soft tissue tumors characterized by a wide spectrum of kinase fusions share a lipofibromatosis-like neural tumor pattern. Genes Chromosomes Cancer.; 59: 575-583

Argani P, Harvey I, Nielsen GP, Takano A, Suurmeijer AJH, Voltaggio L, Zhang L, Sung YS, Stenzinger A, Mechtersheimer G, Dickson BC, Antonescu CR. (2020). EWSR1/FUS-CREB fusions define a distinctive malignant epithelioid neoplasm with predilection for mesothelial-lined cavities. Mod Pathol.; 33:2233-2243.

View All Publications


Dr Cristina R. Antonescu (MD)

Cristina R. Antonescu, MD

Director, Soft Tissue and Bone Pathology

  • My sarcoma research laboratory is dedicated to the detection and molecular characterization of diagnostic and prognostic markers in soft tissue sarcomas. Our current research is focused on 4 areas: (1) KIT oncogenic signaling in the pathogenesis of GIST and mechanisms of drug resistance to targeted kinase inhibitor therapies; (2) oncogenic signaling in angiosarcoma, with the characterization of KDR (VEGFR2) activating mutations in breast angiosarcoma and MYC/FLT4 gene amplifications in radiation-associated angiosarcoma; (3) fusion gene discovery and fusion transcript characterization in diagnosis and prognosis of soft tissue tumors; and (4) establishing genetically engineered sarcoma models using CRISPR-cas9 methodology for investigating the step-wise pathogenesis of translocation-associated sarcomas and generate faithful preclinical models for in vitro drug testing.
[email protected]
Email Address
Office Phone


Laurie Herviou

Research Fellow

William S. Mallen
William S. Mallen

Research Technician

Patricia Sung
Patricia Sung

Senior Research Technician

Fabio Vanoli

Assistant Laboratory Member

Ziyu Xie

Computational Biologist

Lei Zhang

Research Assistant

Lab Alumni
Brigita Meškauskaitė
Brigita Meškauskaitė

Senior Research Technician

Mihai Hajdu

Research Technician

Yun Shao Sung

Research Technician

Antoine Italiano

Research Fellow

Costantino Errani

Research Fellow

Lab Affiliations


  • SPORE in Soft Tissue Sarcoma - Novel therapeutics development and mechanisms of therapeutic resistance in gastrointestinal stromal (2018-2023)
  • EHE Foundation - Molecular and Immune Characterization of EHE Clinical Subtypes (2019-2021)
  • Cycle for Survival - Investigating the Molecular Mechanisms of EWSR1 CREB Gene Fusions in Driving Neoplastic Phenotype across Cell Lineages and Risk of Malignancy (2018-2021)

Get in Touch


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Cristina R. Antonescu discloses the following relationships and financial interests:

No disclosures meeting criteria for time period

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures